Arvinas, Inc. (ARVN) Research

Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.

Market snapshot

Symbol
ARVN
Price
$7.67
Day change
0.00%
Market cap
$494.9M
P/E ratio
-2.22x
52-week range
6.06-14.51
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$14.75

Recent news

  • These Analysts Increase Their Forecasts On Arvinas After Q1 Results

    Arvinas Inc (NASDAQ:ARVN) reported downbeat results for the first quarter on Tuesday.

  • Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer

    Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) stock is trading higher on Tuesday as the company is entering an exclusive global licensing agreement with Arvinas Inc. (NASDAQ:ARVN) and Pfizer Inc. (NYSE:PFE) for its oral PROTAC drug, VEPPANU (vepdegestrant).

  • Rigel strikes licensing deal for Pfizer and Arvinas' breast cancer drug

    Rigel Pharmaceuticals said on Tuesday it has struck a global licensing deal for Arvinas and Pfizer's recently ​approved breast cancer drug, marking Rigel's fourth ‌commercial product on the market.

Peer companies

  • Astria Therapeutics, Inc. (ATXS)
  • ArriVent BioPharma, Inc. Common Stock (AVBP)
  • Day One Biopharmaceuticals, Inc. (DAWN)
  • Ginkgo Bioworks Holdings, Inc. (DNA)
  • Erasca, Inc. (ERAS)
  • Geron Corporation (GERN)
  • Iovance Biotherapeutics, Inc. (IOVA)
  • MeiraGTx Holdings plc (MGTX)

Recent insider activity

  • Cacace Angela M — S-Sale (2576 shares) on 2026-06-17
  • Teel Randy — S-Sale (2209 shares) on 2026-05-21
  • Saik Andrew — S-Sale (11139 shares) on 2026-05-11
  • Loomis David K — S-Sale (1919 shares) on 2026-05-11
  • Cacace Angela M — S-Sale (9657 shares) on 2026-05-11

Open Arvinas, Inc. (ARVN) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.